The muscle-related complications of fasciitis and myositis, caused by chronic GVHD after Allo-SCT are relatively rare, but at times will severely impair a patient's quality of life (QOL). We performed a retrospective analysis in Japanese Allo-SCT recipients to identify the incidence, risk factors and clinical features of fasciitis and myositis. In 1967 patients who underwent Allo-SCT between January 1994 and March 2005 and survived beyond 90 days post transplantation, eight patients developed fasciitis and nine patients developed myositis, with a 5-year cumulative incidence of 0.55% and 0.54%, respectively. The median time from SCT to the development of fasciitis and myositis was 991 and 660 days, respectively. PBSCT was a risk factor for developing fasciitis, but no risk factors were found for myositis. The response to immunosuppressive treatment was better in patients with myositis than fasciitis, and the overall survival after developing these symptoms was better in patients with myositis than those with fasciitis. An early diagnosis by a biopsy, which includes fascia and muscle or magnetic resonance imaging (MRI) and prompt treatment may be important to prevent an impairment of the patient's QOL with persistent disability.
Introduction
Allo-SCT has been an essential part of the treatment of refractory hematopoietic disease such as leukemia and lymphoma. 1 The number of patients who undergo Allo-SCT from various stem cell sources increases every year. GVHD is still a major cause of morbidity and mortality after Allo-SCT and is caused by an immunological reaction against antigens in the SCT recipient by the immunocompetent donor graft. Chronic GVHD occurs in 30-70% of recipients who survived beyond 100 days following transplantation, and it is dependent on the degree of HLA mismatch with the donor and the source of the stem cells. [2] [3] [4] The main target organs of chronic GVHD are skin, eyes, mouth, liver, esophagus, bowel, lung and serosa, and the syndrome has features resembling autoimmune and other immunological disorders such as scleroderma, Sjo¨gren's syndrome, primary biliary cirrhosis, wasting syndrome, bronchiolitis obliterans (BO), immune cytopenias and chronic immunodeficiency. Patients with chronic GVHD have decreased performance status, impaired quality of life (QOL) and an increased risk of mortality. 5, 6 Muscle-related complications, fasciitis [7] [8] [9] and myositis [10] [11] [12] [13] are relatively rare chronic GVHD manifestations, and their clinical features resemble autoimmune eosinophilic fasciitis and idiopathic polymyositis. The new chronic GVHD diagnostic guidelines proposed fasciitis as diagnostic, and myositis as a distinctive sign and symptom of chronic GVHD manifestation. 14 Patients with fasciitis develop skin swelling, and thereafter the skin becomes taut, bound down to the underlying tissue, and irregularly thickened, and thereafter demonstrating multiple small depressed areas, which has been called a 'peau d'orange' (or an orange peel) appearance. 7 Contractures and joint stiffness are also observed. The pathological findings of fasciitis include lymphocytic infiltration in edematous fascia and a subsequent increase of collagen fibers. The infiltration is diffuse and it often extends from the fascia into the interstitium of the muscle. The common clinical symptoms of myositis are moderate-to-severe proximal muscle weakness, myalgia, fever, contractures and skin indurations over the areas of muscle involvement. 12 The majority of patients present with elevated creatinine phosphokinase and aldolase enzymes. The histopathology of muscle biopsies demonstrates the degeneration, necrosis and regeneration of muscle fibers and infiltrates of inflammatory cells. These two diseases have similar manifestations and it is sometimes difficult to make an early diagnosis. In addition, fasciitis and myositis severely impair a patient's QOL and some patients suffer disability from muscle and joint symptoms. However, scant data are found concerning Allo-SCT recipients, and the accurate incidence of the diseases by stem cell source and HLA disparity, as well as the treatment response and prognosis, remain unclear. Here, we present the results of our retrospective analysis of fasciitis and myositis caused by chronic GVHD among Japanese patients who underwent Allo-SCT, and we also identify the incidence, risk factors and clinical features of these diseases.
Materials and methods

Patients
Between January 1994 and March 2005, 1967 Japanese patients who underwent Allo-SCT at 15 centers of the Kanto Study Group for Cell Therapy (KSGCT) and who survived beyond 90 days after transplantation were retrospectively analyzed. Basic transplantation data were obtained from the KSGCT database, but specific data of fasciitis and myositis were obtained by using data collection forms. This study was not a part of any specific protocol; therefore, the patients were not asked to provide their informed consent for the study at the onset of either fasciitis or myositis. The patient characteristics are summarized in Table 1 . The stem cell source included related BMT (R-BMT; n ¼ 645), related PBSCT (R-PBSCT; n ¼ 414), unrelated BMT (UR-BMT; n ¼ 732) and cord blood transplantation (n ¼ 176). Because PBSC harvest has not been performed through the Japan Marrow Donor Program, none of the patients received UR-PBSCT. The median period of the observation was 958 days.
Definition of fasciitis and myositis
The diagnosis of fasciitis was made based on the pathological findings, magnetic resonance imaging (MRI) findings and clinical symptoms. A fascia or muscle biopsy was not mandatory for making a diagnosis. The typical pathological finding of fasciitis was inflammatory cells infiltrating on the fascia. MRI images suggested the presence of inflammation on the fascia (e.g., thickening of fascia). The clinical symptoms included sclerotic skin changes, restriction of joint movement, myalgia, swelling and edema. The diagnosis of myositis was made similarly and Bohan and Peter 15, 16 criteria for polymyositis was also used. The symptoms of myositis included muscle weakness, myalgia, fever and muscle swelling. The increase of serum creatinine phosphokinase or aldolase reflects the destruction of muscle. Other causes of fasciitis or myositis than chronic GVHD were ruled out.
Statistical analysis
To evaluate the potential risk factors for developing fasciitis and myositis, the time-dependent Cox proportional hazard regression model was used for univariate and multivariate analyses. The factors with a P-value of 0.2 or less in the univariate analysis were included in the multivariate analysis. The factors that remained significant were retained in the final model. The factors that correlated with each other were not entered into the model simultaneously.
Survival analyses were performed by the Kaplan-Meier method, 17 and the log-rank test was used for univariate comparisons. The cumulative incidence of fasciitis and myositis was calculated using the Gray 18 method, considering death without fasciitis or myositis as a competing risk, on the basis of information obtained from the patient database. For most of the statistical analyses, SPSS software version 11 (SPSS Inc., Chicago, IL, USA) was used. The analyses of cumulative incidences were carried out with package 'cmprsk' of the R statistical software 2.5.1 (the R Foundation for Statistical Computing, Vienna, Austria; available at http://www.r-project.org). All P-values were two-sided, and differences were considered to be statistically significant when Po0.05. Differences with P-values 40.10 are reported as NS. Table 2 . In the eight patients with fasciitis, there were four men and four women. The median age of the patients was 39 years (range, 20-57 years). The stem cell sources were R-PBSCT in five patients, UR-BMT in two patients and R-BMT from single locus mismatch donor in one patient. Seven patients were matched with their donors for HLA-A, B and DR at the serological level. None of the patients with fasciitis or myositis had HLA DR52, although HLA DR52 is highly associated with idiopathic polymyositis 19 and Couriel et al. 12 reported two cases of chronic GVHD-associated myositis with HLA DR52.
In nine patients with myositis, there were five men and four women. The median age of patients was 39 years (range, 21-56 years). The stem cell sources were R-PBSCT in three patients, UR-BMT in three patients and R-BMT in three patients. Eight patients were serologically matched with their donors at the HLA-A, B and DR loci.
Clinical manifestations and treatment outcome of the patients with fasciitis
The time of onset of the symptoms of fasciitis ranged from 212 to 1726 days after SCT (mean, 991 days). The initial symptoms were a characteristic sclerodermatous skin change, called peau d'orange appearance, and restriction of joint movement, which were observed in five and four patients, respectively (Table 3 ). Other symptoms were edema and swelling in three patients and myalgia in two patients. The affected sites were the forearms in five patients, upper arms in four patients, thighs in four patients, legs in four patients and trunk in three patients ( Table 3 ). The affected sites were symmetrical in all patients.
The MRI images of patients with fasciitis showed high intensity along the fascia in short T1 inversion recovery method (Figures 1a and b) . MRI seems to be a useful modality to determine the extent of inflammation of the fascia. A fascial biopsy was performed in six patients. All Fasciitis and myositis after allogeneic SCT K Oda et al samples showed that the fascia were thickened and loosened, and some showed fibrosis. A patchy lymphocyte infiltration was found on the fibrotic fascia or small aggregates were seen around capillaries (Figure 2a ). Immunostaining of CD4 and CD8 antigens revealed that the infiltrating lymphocytes on the fascia were predominantly CD8 þ T cells, and the CD8:4 ratio was generally 10:3 (Figure 2b and c). No patient had deep sclerodermatous change but some patients demonstrated mild lymphocyte infiltration in the epidermis and dermis.
The laboratory data at onset showed a slight elevation of C-reactive protein (X0.3 mg/mg/dl) in three patients. An eosinophilia X5% was observed in two patients. The serum creatinine phosphokinase level was normal in all cases. In four cases, antinuclear antibodies were positive. Anti-Jo-1 and anti-Scl-70 antibodies were negative in the tested samples.
Preceding chronic GVHD manifestations occurred in six patients, regardless of the time of onset of fasciitis. The most common organ damage involved lung complications in five patients and sicca syndrome in five patients ( Table 2) . The lung diseases included BO in four patients, BO organizing pneumonia (BOOP) in one patient, and interstitial pneumonia in one patient.
The immunosuppressive therapies were intensified or restarted for fasciitis in all patients. Six patients responded to the therapy, but five patients had long-term disability such as joint contracture or indurations of skin. Two patients had progressive disease in spite of extensive immunosuppressive treatment and died of disseminated aspergillosis and of multiple organ failure. As of August 2006, six patients were alive and the 5-year survival after developing fasciitis was 50.0%, according to KaplanMeier's analysis (Figure 3) .
Clinical manifestations and treatment outcome of the patients with myositis
Myositis developed after 124-1548 days (median, 660 days) after SCT. The main clinical manifestations were myalgia in eight patients, muscle weakness in five patients, swelling in five patients and fever in four patients (Table 4 ). The affected sites of myositis were the upper arms in five patients, forearms in four patients, thighs in seven patients, legs in five patients and the trunk in three patients. The symptoms were symmetrical in all patients.
An MRI scan showed high intensity in muscle in fatsuppressed T2 weighed image (Figures 1c and d) . A muscle biopsy, including fascia, was undertaken in six patients. The representative findings were necrosis and reconstruction of muscle cells, irregularity in muscle fibers, interstitial fibrosis and lymphocytic infiltration surrounding the (Figure 2d ). The lymphocytic infiltration was more predominant in the endomysium than in the perimysium. Immunostaining of CD4 and CD8 revealed that the CD8 þ T cells were dominant, with a CD8:4 ratio of approximately 2:1 (Figures 2e and f) . Electromyography was examined in seven of nine patients and showed myopathic changes. The serum C-reactive protein was elevated in eight of nine patients. Three patients had eosinophilia (X5%) and eight patients had elevated transaminases. All patients had elevated levels of creatinine phosphokinase (maximum, 4864 U/l). Rheumatoid factor and antinuclear antibodies were present in two cases. Anti-Jo-1 and anti-Scl-70 antibodies were negative. All patients had preceding chronic GVHD manifestations other than myositis. The main symptoms of chronic GVHD involved the oral mucosa in five patients, the skin in five patients, sicca syndrome in four patients and liver disease in four patients.
All patients responded to immunosuppressive treatment. One patient relapsed after tapering the immunosuppressive treatment, but was successfully treated by increasing the immunosuppression. 20 As of August 2006, all patients are alive. Two patients had residual disabilities, which included muscle atrophy and deformity of vertebrae caused by muscle weakness. The overall survival rate after the onset of myositis was 100% (Figure 3 ).
Risk factors for developing fasciitis and myositis
Related PBSCT was a significant risk factor for developing fasciitis in comparison with BMT by multivariate analysis (the hazard ratio: 7.474, P ¼ 0.006; Table 5 ). There were no other significant risk factors for developing fasciitis such as a conditioning regimen or acute GVHD, although GVHD prophylaxis with FK506 was a significant factor in univariate analysis (Table 6 ). For myositis, there were no significant risk factors in univariate analysis (data not shown).
Discussion
In this study, the 5-year cumulative incidence of fasciitis and myositis by chronic GVHD was 0. 55 and 0.54%, respectively, which were lower than those of previous reports. Janin et al. 7 reported that 14 out of 475 patients (2.9%) who underwent Allo-BMT from an HLA-identical sibling donor developed fasciitis. Parker et al.
10 also showed that the rate of polymyositis among patients who developed chronic GVHD after Allo-BMT from a sibling donor was 3.4%. In this study, only one patient, who underwent R-BMT from an HLA-single locus mismatched donor, developed fasciitis out of 645 R-BMT recipients. No one with R-BMT from an HLA-identical donor developed fasciitis and only two patients of 732 UR-BMT recipients developed fasciitis. We had no fasciitis or myositis in the cord blood transplantation recipients.
For fasciitis, R-PBSCT was a significant risk factor compared to other stem cell sources, and no risk factors were found for myositis. Flowers et al. 21 reported that chronic GVHD after PBSCT might be more protracted and more refractory than after BMT. They also reported that skin involvement was more frequent in PBSCT recipients than in BMT recipients. It is interesting that R-PBSCT patients were also associated with the development of fasciitis as well as skin involvement, even though the mechanisms are unknown.
As compared with westerners, the incidence of chronic GVHD in Japanese is lower and its manifestation is slightly different. 4, 22 Atsuta et al. 22 reported that prognostic scoring systems, which were developed on the basis of clinical findings for western patients, did not produce an effective categorization for Japanese patients. The proportion of a progressive type onset of chronic GVHD in Japanese patients is much lower than that in western countries, and the extent of cutaneous chronic GVHD was also different. 23 This may be explained by the great genetic homogeneity of the Japanese population. However, because of the retrospective nature of this study, there is a possibility that mild form of fasciitis and scleroderma might have missed, thereby , underestimating their incidence.
In fasciitis and myositis, CD8 þ T cells were predominantly infiltrated in both fasciitis and myositis. Kojima et al. 24 reported the clonal expansion of limited T-cell clonotypes in affected muscle of post-transplant myositis patients. The alloreactive T cells may expand in muscle or fascia through stimulation by limited kinds of antigens. If fasciitis or myositis is suspected, a deep biopsy including skin, subcutaneous fat, intermediate septa, fascia and muscle should be performed for proper diagnosis. However, it might not be mandatory for making a diagnosis of fasciitis or myositis, because an MRI scan is useful in the context of other symptoms and clinical and laboratory data, and it can effectively confirm the affected lesions. Almost all patients with fasciitis or myositis were complicated with other manifestations of chronic GVHD, but there were different tendencies regarding the involved organs among the patients with fasciitis and myositis. In patients with fasciitis, lung disease (BO) and sicca syndrome were more frequent than oral and skin involvement. Pulmonary complications will affect the patient's prognosis, because they can cause severe respiratory failure. So the fact that patients with fasciitis tend to have pulmonary complications might be related to their poor prognosis. Some authors reported severe respiratory failure caused by weakness of respiratory muscles in patients with myositis, 25, 26 but we had no myositis patients with respiratory failure.
Previous reports have indicated that steroid treatment generally worked well for patients with eosinophilic fasciitis. 8, 27 On the other hand, fasciitis caused by chronic GVHD often seemed to result in functional disabilities such as skin tightness, severe joint stiffness and joint contracture, despite continuous steroid therapy and other immunosuppressive treatment for chronic GVHD. 7 In myositis, some reported cases showed a recurrence with either a reduction or cessation of immunosuppressant therapy. [10] [11] [12] 20 One of our patients also had recurrent acute myositis after CsA was tapered, and achieved a second remission of polymyositis with CsA. 20 We need to recognize that both fasciitis and myositis caused by chronic GVHD can result in disabilities that reduce the patient's QOL. We have to make an early diagnosis and promptly treat fasciitis and myositis to prevent the progression of the complications.
In conclusion, we identified the incidence of fasciitis and myositis as chronic GVHD manifestations according to various stem cell sources and found that R-PBSCT was a significant risk factor for fasciitis. Because the treatment response for myositis was fairly good, an early diagnosis by a biopsy, which includes fascia and muscle or MRI, and prompt treatment are important to prevent impairment of the patient's QOL with persistent disability.
